Skip to content

Author

S. Gobec

We have 4 of 54 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Novel NIR DDNP-type solvatochromic and fluorogenic probes for amyloid β detection.

Selective near-infrared fluorescent probes for amyloid β aggregates are of considerable interest as molecular imaging tools for the diagnosis and study of Alzheimer's disease. Herein, we describe the rational design and synthesis of DDNP-type donor-π-acceptor fluorophores incorporating a fixed N,N-dimethylamino donor g...

Matic Rogan, L. Blinc, Luka Rejc et al. · 0 citations
Open access Oct 2026

Synthesis of 3-Amino-4-(Hydroxymethyl)-β-Lactam Branch Point and Its Late-Stage C4 Functionalization with Ceftaroline-Sidechain Monobactams and Their Biological Evaluation

Two alternative routes to 3-amino-4-(hydroxymethyl)-2-azetidinone are compared, a synthon carrying handles at N1, C3 and C4, starting from ethyl glyoxylate and from (R)-glyceraldehyde acetonide, which replaces a low-yielding NaBH4 ester reduction with a near-quantitative oxidative cleavage/reduction sequence.

Vid Kavaš, Majda Golob, A. Meden et al. · 0 citations
Open access Sep 2026

223. Multidomain behavioural profiling in the Flinders Sensitive Line rat and response to escitalopram or a novel butyrylcholinesterase inhibitor: focus on anhedonia

The comparable efficacy of ESC and BChEI in reversing CPP deficits highlights the therapeutic responsiveness of consummatory anhedonia, strengthening the translational validity of the FSL model and position the BChE-ghrelin-dopamine pathway as a promising avenue for further mechanistic exploration in MDD research.

N. Olivier, C. Brink, A. Haasbroek-Pheiffer et al. · 0 citations
Open access Sep 2026

437. Development of novel add-on treatment of cognitive dysfunction in schizophrenia

Preliminary data show that the butyryl cholinesterase inhibitor GUK1811 could modulate glutmatergic transmission in the hippocampus, and may, thus, have a potential to ameliorate cognitive dysfunction related to this brain region in schizophrenia.

K. Jardemark, J. Bruton, M. Shahid et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.